crinecerfont
chemical compound
≈ 1 min read
crinecerfont. encyclopegia.org, snapshot crinecerfont-3048817-ad20a57c22a6510c. /a/crinecerfont
Names in other languages
- Englishcrinecerfont
- FrançaisCrinecerfont
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Crinecerfont, sold under the brand name Crenessity, is a medication used for the treatment of congenital adrenal hyperplasia. It is a corticotropin-releasing factor type 1 receptor (CRF1R) antagonist developed to treat classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD). It is taken by mouth.
The most common side effects of crinecerfont in adults include fatigue, dizziness, and arthralgia (joint pain). For children, the most common side effects include headache, abdominal pain, and fatigue. Crinecerfont was approved for medical use in the United States in December 2024.
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1364270559 under CC BY-SA 4.0; modifications have been made.